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The Aortic Valve: Structure, Complications and Implications for 
Transcatheter Aortic Valve Replacement 
MM Rozeik, DJ Wheatley and T Gourlay 
 
Abstract 
The aortic valve operates in a complex hemodynamic environment, opening and closing over 100,000 
times a day. When complications arise such as aortic stenosis, prognosis can be very poor, leading to 
death within the first few years. Surgical valve replacement is currently the standard treatment for aortic 
stenosis. A thorough understanding of the anatomy and function of the native valve is imperative when 
developing a prosthetic replacement that can withstand the complex demands of the heart. This review 
focuses on the anatomy, structure and disease of the aortic valve and the implications for a transcatheter 
aortic valve replacement (TAVR). Current complications with TAVR such as major vascular bleeding, 
conduction disturbances and patient-prosthesis mismatch (PPM) can be overcome by reducing the 
delivery profile and through use of more accurate imaging technologies to work towards a fully 
functional and durable prosthesis. 
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Introduction 
 
The aortic valve directs a one way forward flow of blood from the left ventricle of the heart 
to the rest of the body with minimal regurgitation and pressure drop.
1
 These delicate and thin 
leaflet structures are subjected to a lot of rapid tensile, shear and bending stresses, opening 
and closing approximately 100,000 times a day and about 3.7 billion times in an average life-
span. Historically, they were considered to react passively to regulate blood flow to keep us 
alive. However, it is now readily becoming accepted that the aortic valve undergoes a series 
of complex operations at the cellular and molecular level to maintain their function in the 
extreme hemodynamic and mechanical environments.
2
 When these valves are congenitally 
malformed, diseased or subjected to trauma, their function is compromised leading to 
complications such as heart failure and eventual death if left untreated. In severe cases, 
surgical replacement with a prosthetic valve is the gold standard treatment. Aortic stenosis 
(AS) is the most prevalent disease. However, 33% of patients over the age of 75 with severe 
symptomatic AS are refused surgery due to the increased risk related to age and left 
ventricular function.
3
 Transcatheter aortic valve replacement (TAVR) enables patients to 
receive a prosthetic heart without the need for open heart surgery. Since the first human 
intervention in 2002, there have been over 50,000 TAVR procedures.
4, 5
 However, these 
valves can introduce the patient to other complications such as major vascular bleeding and 
stroke. A correct understanding of the anatomy of the aortic root is therefore vital when 
considering the design of a prosthetic valve, particularly in the case of a transcatheter 
delivered valve which sandwiches the native leaflets between the stent and the aortic wall and 
may create an obstruction to flow. The following sections of this review focus on the aortic 
YDOYH¶VDQDWRP\SDWKRORJ\ the existing surgical replacement valves available and the 
implications for a percutaneous heart valve.  
Gross anatomy and location 
 
The aortic valve consists of three semi-lunar shaped leaflets and three dilations known as the 
sinuses of Valsalva. It lies within the aortic root which bridges the left ventricle to the 
2 
 
ascending aorta.
6
 The base of the valve leaflets lie just below the anatomical ventriculo-
arterial junction on a virtual ring known as the basal attachment.
7
 It is this anatomical 
location between the ventricle and aorta that surgeons use to suture a valvular prosthesis.
8
 
The sinuses interject with the ascending aorta at a ring known as the sinotubular junction. In 
two of the sinuses lie the coronary ostia which give rise to the right and left coronary arteries. 
Thus, the sinuses are regarded as the right and left coronary sinuses respectively, and the 
third sinus is the non-coronary (or posterior) sinus.
1
 The sinuses have a scalloped or crown 
like border running from the basal attachment to the sinotubular junction to which the semi-
lunar side of the leaflets attach, creating a hinge on which the leaflets flex. Cut-aways of the 
heart exposing the anatomical position of the aortic valve and of the aorta are shown in 
Figures 1 and 2 respectively. 
 
 
Figure 1. Anatomical position of the aortic valve in relation to the left ventricle, left atrium and ascending aorta 
of the heart. Green line shows the basal attachment of the aortic leaflets.7 
 
 
Figure 2. Cut away of the aorta showing the semilunar leaflets, sinuses of Valsalva and the coronary ostia.9 
 
Three fibrous inter-leaflet triangles form between the leaflets and the basal attachment. The 
inter-leaflet triangle between the posterior and left leaflet are in fibrous continuity with the 
anterior leaflet of the bicuspid mitral valve (Figure 2). Thus a low placement of the valvular 
prosthesis within the left ventricular outflow tract (LVOT) may result in impingement on the 
mitral leaflet.
7
 The triangle between the right and posterior leaflet is connected to the 
membranous part of the ventricular septum. In congenitally deformed valves, these triangles 
have been observed to be inadequately formed, providing a more annular shape than normal.
8, 
10
  
 
The leaflets can be considered to form part of a cylinder as they are flexed circumferentially 
but are flat in the radial direction. This enables them to easily reverse curvature during valve 
opening and closure.
1
 The free edges of the leaflets come together at an angle of 120° to 
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prevent the back flow of blood.
11
 The line of attachment where the leaflets come together 
distally is known as the commissures, which transfer the load from the leaflets to the aortic 
wall. The region where the free edges overlap is known as the coaptation region (or lunula), 
and forms due to a bend in the radial plane of the leaflets. This region functions to transfer 
the pressure load from the centre of the leaflets to the commissures.
1
 Fibres form a thickened 
nodule at the centre of the free edges known as the node of Arantius which help to ensure full 
coaptation. 
 
Valve dynamics 
 
During ventricular systole, pressure in the left ventricle rises and overcomes the pressure in 
the aorta. This results in a rapid opening of the aortic valve with minimal resistance to blood 
flow. Blood reaches a peak velocity of approximately 1.35 ± 0.35 m/s in the first third of the 
cycle before decelerating and reversing flow. Ideally, the aortic valve would be required to 
open rapidly with minimal resistance. In a healthy valve, it typically opens in 20-30 ms. The 
deceleration reverses the pressure gradient, forcing the edges of the leaflets to come together 
and rapidly shut the valve with minimal regurgitation. The closing volume has been noted to 
be less than 5% of the forward flow. Whilst the pressure gradient across the open valve is less 
than 10 mmHg in a healthy valve, typical closing pressures are 80 - 100 mmHg.
12
  
 
During forward flow some of the blood coils around the sinus edge, which then decelerates 
and forms eddy currents before returning to the mainstream flow. This action was first 
reported by Leonardo da Vinci in 1513 who observed vortices forming behind the leaflets of 
valves mounted on a glass model of the aortic root.
13
 Similar experiments were carried out by 
%HOOKRXVHDQG7DOERWZKLFKDJUHHGZLWKGD9LQFL¶VILQGLQJVRQ the role of the sinuses.14 The 
vortices keep the leaflets afloat and create a pressure gradient on the lateral aspect of the 
leaflets in relation to the centre, pushing them together. If the sinuses were removed, the 
reversal pressure gradient of the mainstream flow is capable of valve closure but with less 
speed and efficiency. During diastole, when pressure in the ventricle drops below the aortic 
pressure, blood in the sinuses flows into the coronary arteries through the right and left 
coronary ostia. 
 
The velocity profile of the blood flow through the aortic valve is laminar and typically flat 
although there is a slight skew caused by the orientation of the valve to the long axis of the 
left ventricle.
12
 Although the aortic valve has generally been considered to react passively to 
the flow of blood, it in fact reacts dynamically to the hemodynamic changes during the 
cardiac cycle. For example, the base perimeter is largest at the end of diastole due to the 
LVOT and decreases by 9-22% at the end of systole.
1
 The radius of the commissures also 
expands outwardly by 12% in systole and decreases by 16% in diastole.
15, 16
 Additionally the 
leaflets are found to contract circumferentially during systole to increase the orifice area and 
extend radially during diastole to provide full coaptation.
17
 It has been suggested that the 
design of the prosthetic aortic valve should be based on the dimensions of the valve at mid-
diastole.
16
 
 
Structure of the leaflets 
 
The cellular constituents of the aortic valve can be divided into two types; the valvular 
endocardial cells (VEC) and the valvular interstitial cells (VIC). Together, these cells interact 
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in a complex hemodynamic and mechanical environment to regulate the valve.
18
 The VEC 
encases all heart valves and serves as a non-thrombogenic barrier between the blood and 
leaflets. Their phenotypes have been found to be distinctly different from vascular endothelial 
cells. Additionally, they have been found to align perpendicular to the direction of shear 
stress whereas vascular endothelial cells are aligned parallel to the direction of flow.
18
 VECs 
on the aortic and ventricular sides have also been reported to be intrinsically different. 
Calcification of the aortic valve originates from endothelial dysfunction and occurs on the 
aortic side of the leaflet.
2
 It is possible that the greater shear stress exposed by the ventricular 
side increases the resistance of its VECs. 
 
The VIC has characteristics between smooth muscle cells and fibroblasts and forms a 
network across the extracellular matrix (ECM) of the leaflets.
19, 20
 It has been suggested that 
the VIC have several phenotypes including smooth muscle cells, myofibroblasts and 
fibroblasts. They exhibit contractile properties and regulate and synthesize components of the 
ECM.
2, 21
 Contractile properties have been suppoUWHGE\HYLGHQFHRIĮ-smooth muscle actin 
expression when VICs were cultured in vitro. Additionally, they are involved in the inherent 
repair of the valve which is subjected to damage due to the complex hemodynamic 
environment and their absence in prosthetic valves may be a cause for structural failure.
18
 
 
Due to their thin structure, the leaflets are practically avascular and obtain their nutrients 
from the surrounding blood. Interestingly, they have been found to be richly innervated, 
particularly on the ventricular side of the leaflet, apart from the lunula. Their significance is 
still not clearly understood but structural changes in response to neuromodulators may 
suggest adaptations to mechanical properties to cope with various pathologies such as 
hypertension.
22
 
 
The ECM primarily consists of collagen, elastin and proteoglycans, each accounting for 60%, 
10% and 20% of the dry weight of the valve respectively (Kunzelman et al.
23
 cited by 
Flanagan and Pandit).
19
 Collagen provides the valve leaflet with much of its mechanical 
strength whilst the elastin provides interconnections between the fibres and helps restore the 
collagen to its natural crimped state.
24
 Proteoglycans are highly hydrophilic which act as 
shock absorbers during the dynamic changes in the valve.
2
 
 
The leaflets of all valves are comprised of three layers; the fibrosa, spongiosa and 
ventricularis (atrioventricular valves also contain an atrialis layer which forms part of the 
spongiosa). These terms were first coined in 1931 by Gross and Kugel who carried out a 
thorough study on the topographical anatomy and histology of heart valves in an attempt to 
address mechanisms of valve failure.
25
 The fibrosa is the thickest layer, consisting primarily 
of a dense network of type I collagen fibres arranged circumferentially. It appears to be the 
main loading bearer and extends throughout the whole of the tissue.
11
 Collagen fibres have 
been found to be aligned circumferentially at the commissures which become more highly 
aligned in loading. 
 
The ventricularis is a dense network of collagen and elastin fibres which face the ventricular 
chamber. The elastin fibres appear to be radially aligned which assists in reducing radial 
strains caused by fluid flow when the valve is fully open. Between the fibrosa and 
ventricularis is a watery connective tissue known as the spongiosa. This layer contains a high 
concentration of glycosaminoglycans and proteoglycans which are believed to lubricate the 
adjacent layers as they shear and deform relative to each other during leaflet flexure and 
pressurization.
1, 26
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Mechanical properties 
 
Due to the circumferential and radial alignments of the collagen and elastin fibres, the valve 
leaflets have anisotropic and complex viscoelastic mechanical properties.
27
 The structural 
deformation of the aortic valve can be divided into two mechanisms; flexure and tension.
28
 
Flexion occurs during leaflet opening and closure whilst tension occurs during full loading 
from the diastolic pressures. Loading aligns and straightens out the crimped collagen fibres 
along the direction of the force which results in an initial toe region as the collagen 
straightens out followed by a rapid linear response in a stress-strain graph (Figure 3a). The 
leaflets are significantly stiffer in the circumferential rather than the radial direction. In a 
study by Kalejs et al. the elastic modulus of human aortic valve was calculated to be 15.34 ± 
3.5 MPa in the circumferential direction and 1.98 ± 0.24 MPa in the radial direction.
29
 
 
 
 
Figure 3. (a) Mechanical response of collagen and elastin during the cardiac cycle and (b) schematic 
representation of the aortic leaflet during systole and diastole.30 
 
The leaflets are viscoelastic, meaning that their mechanical properties exhibit both elastic and 
viscous characteristics. In time dependant studies, the mechanical properties of aortic leaflets 
were found to be independent of strain rate. They were also found to exhibit continued stress 
relaxation but had negligible creep over a period of three hours.
11
 Materials exhibiting stress 
relaxation have a gradual decrease in stress at a constant strain which is beneficial during the 
diastolic phase of the cardiac cycle. Creep is an undesirable characteristic since it would 
permit the leaflets to gradually stretch with time when subjected to a fixed load which could 
lead to a prolapsed leaflet.  
 
In flexion tests, the ventricularis was found to support the leaflet in tension when flexed with 
the curvature of the leaflets, i.e. when the valve is open. The elastin fibres arranged radially in 
the ventricularis enable the leaflet to extend radially for full coaptation; enabling it to handle 
strains of 60%. However, the elastin in the fibrosa was shown to have minimal involvement 
in the radial or circumferential directions.
24
 In a study by Mirnajafi et al., the flexural 
stiffness at the belly region of the aortic valve was found to be three times that of the 
commissures. It was also found to be higher when the commissures were flexed in the non-
physiological reverse direction and decreased with increasing flexion angle in both directions. 
The decrease was attributed to local tissue buckling which reduced the effective thickness of 
the leaflet.
31
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Valvular diseases 
 
Diseases of the heart valves compromise the normal valvular function leading to other 
complications to the surrounding structures. They may be caused by a variety of factors 
including congenital defects, age, lifestyle habits, trauma or infection. The following sections 
focus on the main valvular complications which arise from congenital deformations or due to 
degenerative disease.  
 
Bicuspid aortic valves 
 
Congenital valve defects range from a missing or complete closure of the valve as in aortic 
atresia, to sub-aortic or supra-valvular stenosis due to a narrowing of the left ventricular or 
aortic tract respectively, to poor formation of the valve cusps. The most common congenital 
abnormality is the bicuspid aortic valve (BAV), where two leaflets are fused together to form 
a single large leaflet. This occurs in 1-2% of the population and is more prevalent in males.
32
 
Certain characteristics define a BAV including leaflets of different sizes, a central raphe 
between the largest leaflet and a smooth leaflet margin even when diseased.
33
 Difference in 
leaflet size occurs in 92% of BAV cases and most prevalent (86%) between the right and left 
coronary leaflets.
34
 The disease is thought to be genetic since it is highly associated with 
other abnormalities of the aorta such as aortic coarctation. Additionally it has been 
hypothesised that a lack of microfibrillar proteins during valvulogenesis may disrupt full 
development of the valve leaflets as well as create a weakened aortic root structure.
35
  
 
The incidence of patients with AS (a narrowing of the valve aperture) having a bicuspid, uni-
cuspid or (rarely) quadri-cuspid valve
36
 is particularly high.
1
 The geometry of the valve has 
also been shown to play a role in leaflet calcification, thereby indicating a need to develop a 
valve with a native tri-leaflet design. Thubrikar noted that the greater the deviation from the 
normal design, the greater the number of valve replacements and the younger the patient 
needing replacement.
1
 
 
As well as AS, congenital valvular abnormalities are also associated with aortic regurgitation, 
infective endocarditis, and aortic complications such as root dilation, aneurysms and 
dissection.
35
 The occurrence of infective endocarditis in patients with BAV were found to 
range from 12% - 39% in surgical and autopsy studies.
34
  Many patients with BAV have 
dilations of the aortic root, sinotubular junction, ascending aorta and aortic arch. These 
dilated structures lead to abnormal hemodynamics and shear stresses, which can accelerate 
calcific degeneration of the valve. BAV is commonly asymptomatic from birth and the 
patient can function normally for 50-60 years before symptoms arise. Symptoms detected 
from early childhood are generally due to severe valvular disease. 
 
Aortic stenosis 
 
Aortic Stenosis (AS) is a narrowing of the valve aperture, reducing the aortic valve area and 
increasing resistance to blood flow, thereby increasing the transvalvular pressure gradient. 
This obstruction increases the workload of the left ventricle leading to ventricular 
hypertrophy, although the ejection volume remains the same. In a random population study of 
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11,911 adults, the mass of the left ventricle was found to increase from 171.1 ± 70.1 g with a 
normal valve to 198.7 ± 80.9 g in patients with AS, suggesting ventricular hypertrophy.
37
 The 
most common cause is calcific degeneration leading to stiffening and calcification of the tri-
leaflet valve and restricting the motion of the leaflets. It can also be caused from Rheumatic 
fever due to inflammation of the leaflets although prevalence of this has decreased in 
developed countries. 
 
Mechanisms of calcification in the valve seem to stem from disruption of the endocardium 
lining the aortic side which may be caused by increased mechanical stress or a decrease in 
shear stress. Additionally, the posterior leaflet is usually the first to be affected and this 
leaflet has a reduced shear stress compared to the left and right coronary leaflets due to the 
absence of the coronary ostia.
38
 Calcific nodules form on the aortic side and at the base of 
leaflets and the histological process has been likened to atherosclerosis. Lipids are seen to 
infiltrate through the endocardial lesion and accumulate within the sub-endocardial and 
fibrosa layers. Low density lipoproteins are oxidised and are then taken up by macrophages 
to produce foam cells. Additionally, inflammatory cells such as macrophages and T-cells 
infiltrate through the lesion, releasing cytokines which remodel the extracellular matrix. A 
subset of myofibroblasts in the fibrosa layer has been shown to differentiate into an osteoblast 
phenotype which is capable of producing calcific nodules (Figure 4). 
 
  
Figure 4. Photograph of a minimally diseased aortic valve and a severely calcified aortic valve. Arrow points to 
lipo-calcific changes to the aortic side although the commissures are spared.38  
 
Based on the results of the Euro Heart Survey on Valvular Heart Disease, AS was prevalent 
in 33.9% of patients with a single native heart disease, making it the most common valvular 
disease in Europe and America.
39
 The prevalence of AS increases with age and can be as high 
as 4.6% in people over the age of 75.
37
 As the age of the population increases it is likely that 
the prevalence of AS is onset to increase annually. It is estimated that 3.5 million people in 
England will have AS by 2020, amongst which 4.3% would be classified as severe.
40
  
 
AS may be symptomatic; exhibiting symptoms of angina, syncope or heart failure, or be 
asymptomatic.
41
 In symptomatic or severe cases prognosis is poor, with death occurring in 
one to two years following symptom onset and the valve would require replacement through 
surgical intervention. The ACC/AHA guidelines grade severe AS occurring when the orifice 
area is less than 1.0 cm
2
, the mean gradient is greater than 40 mmHg or the jet velocity is 
greater than 4 m/s.
41
 In milder forms of AS with areas between 1 and 1.5 cm
2
 and velocities 
between 3 and 4 m/s, surgery is considered if calcification is significant.
42
 However, 
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approximately 30% of patients with severe AS over the age of 75 years do not undergo valve 
surgery due to technical complications such as a porcelain aorta, due to patient refusal, 
general frailty or serious comorbidity such as renal dysfunction.
43
  
 
Aortic regurgitation 
 
Aortic regurgitation (or insufficiency) is caused by abnormalities to the aortic leaflets or 
aortic root, resulting in a leakage of blood from the aorta to the left ventricle when the valve 
is closed. Before antibiotic treatment was available, the most prevalent cause of aortic 
regurgitation used to be Rheumatic fever. Nowadays, it is more commonly caused by 
insufficient leaflet coaptation due to calcific degeneration, congenital defects and infective 
endocarditis.
44-46
 Other causes include trauma leading to perforations, cusp bending or a 
prolapsed leaflet.
47, 48
 In chronic cases, the left ventricular volume leads to ventricular 
hypertrophy and recruitment of sarcomeres to accommodate the increase in volume.
32
 
Therefore a normal physiological stroke volume and ventricular diastolic pressure are 
maintained. Patients with chronic aortic regurgitation may be asymptomatic for decades.
49
 
Complex murmurs may be heard which include an early mid-systolic murmur as the left 
ventricle rapidly ejects the overload of blood and a holodyastolic murmur corresponding to 
early closure of the mitral valve in response to the increased left ventricular volume. A 
rumbling late diastolic murmur known as the Austin Flint murmur may be also heard 
corresponding to the partial or complete closure of the mitral valve during ventricular diastole 
due to the regurgitant jet flow from the aortic valve. In patients with acute aortic 
regurgitation, enlargement of the left ventricle does not occur to accommodate the extra 
volume. Consequently, there is a decrease in stroke volume which leads to tachycardia to 
increase the cardiac output. However, usually the increase in heart rate is insufficient to cope 
with the demand leading to pulmonary oedema (due to an increase in left atrial pressure) and 
cardiogenic shock.  
 
Indications for valve replacement surgery 
 
Generally, there are no effective treatments for AS or regurgitation except aortic valve 
replacement (AVR).
50
 Additionally, there is no proof that medical treatment could prevent or 
delay valve disease.
40, 49
 Balloon valvotomy could be used as a bridge to surgery to provide 
temporary relief of symptoms but is not recommended as an alternative to AVR. Patients 
with symptomatic severe AS and those with severe AS also undergoing other cardiac 
procedures such as coronary artery bypass graft (CABG) surgery have a poor prognosis 
following onset of symptoms and are indicated for aortic valve replacement.
49
 
 
The severity of AS can be determined from diagnostic measurements to measure the effective 
orifice area (EOA), the jet velocity, the ejection fraction and transvalvular pressure gradients.  
 
There are several approaches to determining the EOA of the stenosed valve. The most 
common method is the Gorlin formula (1) which is defined as: 
 
   
PC ' 3.44SEPHR
CO
A          (1) 
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Where  A is the orifice area of the valve (cm
2
), CO is the cardiac output (cm
3
/min), HR is the 
heart rate in beats/min, SEP is the systolic ejection period in seconds per heart beat, 44.3C is 
an empirical constant (C is assumed to be 1.0 for the aortic valve)DQGǻ3LVWKH transvalvular 
pressure gradient in mmHg. 
 
Another equation which is often used is the continuity equation (2), which states that the flow 
rate in the LVOT is equal to the flow in the vena contracta (VC).
51
  
 
    ൌ ୅ై౒ో౐୚୘୍ై౒ో౐୚୘୍౒ి ൌ ୗ୚୚୘୍౒ి          (2) 
 
Where A is the geometric area, VTI is the velocity time integral and SV is the stroke volume.  
 
Either cardiac catheterization or Doppler echocardiography is used depending on whether the 
Gorlin equation or the continuity equation is used respectively. Doppler echocardiography 
would estimate the EOA based on the VTI at the vena contracta, which would give the 
smallest cross-sectional area of the stream. However, this method is likely to overestimate the 
severity of the AS which may lead to an unnecessary indication for valve replacement 
surgery. Patients with mild AS may be incorrectly indicated for valve replacement if they 
appear to have a high transvalvular gradient. An infusion of nitroprusside or dobutamine 
would increase the outflow and the calculated aortic area and only slightly increases the 
gradient, which would reduce the severity of the AS. In patients with severe AS, 
nitroprusside or dobutamine increases the gradient substantially but only mildly increases the 
area, if at all. 
 
Surgical aortic valve replacement 
History of valvular surgery 
 
Surgery on the valve can be traced back to as early as 1912 when Dr. Theodore Tuffier, a 
French surgeon, used his finger to push the aortic wall to free the fused leaflets of a stenosed 
aortic valve.
52
 Since then, initial attempts on valve repair before the introduction of the 
cardiopulmonary bypass (CPB) involved mitral valve commissurotomy through access from 
the atrial chamber. In 1948, Thomas Holmes Sellors used a tenotomy knife to perform the 
first pulmonary valvulotomy through the right ventricle.
53
 Charles Hufnagel developed the 
first artificial valve based on a reciprocating ball in a cage which was inserted rapidly into the 
descending aorta to reduce the amount of blood flowing back into the ventricles due to aortic 
insufficiency.
54
 Following the invention of the CPB machine, heart valve replacement in the 
anatomical position of the native valves rapidly took off. The first successful aortic valve 
replacement (AVR) was performed by Dr. Dwight Harken and colleagues using a ball-cage 
valve. In the same year, Dr. Albert Starr and Lowell Edwards implanted their own caged-ball 
valve in the mitral position.
55
 It is important to emphasize that no artificial heart valve 
developed can ever replace the native aortic valve in terms of its adaptability to complex 
hemodynamic environments. Accordingly, repair or preservation of the diseased aortic valve 
should be considered wherever possible. The choice of valve depends on the age and well-
being of the patient. Bio-prosthetic valves have a similar hydrodynamic function to the 
natural aortic valve but have a limited life expectancy. Mechanical valves are more durable 
but require constant anti-coagulation treatment. These valves are discussed in further detail 
below. 
10 
 
Mechanical valves 
 
Mechanical heart valves typically have a longer lifespan than bioprosthetic valves; lasting 
approximately 25 years and so would not require frequent replacement as is the case with 
bioprosthetic valves. Since 1960, over 70 different mechanical heart valve designs have been 
developed.
56
 Amongst the most common are the ball and cage valve, the tilting disc and the 
bi-leaflet (Figure 5).  ,QWKHHDUO\¶V&KDUOHV+XIQDJHOGHYHORSHGD plastic tube with a 
ball occluder which functioned as a valve assist device to adequately control the flow of 
blood in the descending aorta of patients with aortic regurgitation. More than 200 valves were 
implanted in the descending thoracic aorta of patients, with some valves achieving 30 years 
of function with minimal wear.
57
 The ball valve was modified by Dr. Albert Starr and Lowell 
Edwards who developed a cage made initially from Lucite with a silicone elastomer ball. The 
cage material was changed to stainless steel and then Stellite 21. The valve, known as the 
Starr-Edwards valve had a Teflon sewing ring which enabled suturing into the mitral position 
and later the aortic position.
55
  
 
This valve design underwent several modifications to reduce thrombogenicity such as 
covering the struts with cloth to reduce metal contact with blood, having streamlined struts 
and a silastic shield. However, excessive rubbing of the ball against the sewing ring caused 
abrasion which increased haemolysis. Additionally, the valve had a high profile which was 
found to occlude the coronary ostia. Despite the initial complications, the Starr-Edwards 
valve demonstrated the feasibility of prosthetic valves and enabled them to draw up a design 
criteria. This covered several fundamental points including that the valve should be; a) 
chemically inert, b) biocompatible, c) atraumatic to blood and d) non-thrombogenic.
58
 In 
1965, a non-rotating disc valve known as the Kay-Shiley valve replaced the ball with a single 
disc to reduce the profile of the valves. Other similar designs emerged with Delrin discs, a 
poly-acetal homopolymer. However, high energy losses resulted from lateral flow of blood 
past the disc surface which led to poor hemodynamics such as high pressure drop and 
haemolysis. These valves were soon discontinued. 
 
A tilting-disc valve was developed by Bjork-Shiley in 1969 and overcame the problems with 
the single-disc valve. The disc freely rotates between metal struts, which enable it to open by 
tilting at an angle of 60°. Originally this valve was made from Delrin, but this was soon 
replaced with Isotropic Pyrolytic Carbon (PyC) which had excellent hemocompatibility. In 
1975, Bjork-Shiley replaced the flat disc with a convexo-concaved one to enable the disc to 
slide by 2 mm to create a larger orifice. However, the welded struts were found to fracture, 
leading to a product recall for the 70° valves in 1983 and the 60° valves in 1986.
59
 Structural 
failure of the valve in the aortic position led to occlusion, severe acute regurgitation and death 
within minutes. 
 
The most common tilting disc valve to date was developed by Dr Karl Hall and Robert 
Kaster, which was later known as the Medtronic Hall valve. It had a thin strut and a 
perforation in the middle of the disc as a guide, and an improved tilting angle of 75° in their 
aortic valves.
60
 Early complications with this valve included friction and wear of the disc on 
the struts, and fracture of the struts caused by high mechanical loading during closure.  
 
The bi-leaflet valve was developed by St. Jude Medical in 1977. It consists of two semi-
circular flaps made from PyC with the hinges close to the centre of the orifice. This creates 
three orifices for blood to flow through, which increases the blood contact surface area but 
has a higher EOA than the tilting disc or ball and cage valves. The EOA was found to 
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increase from 1.5 - 2.1 cm
2 
in the tilting disc to 2.4 - 3.2 cm
2
 in the bi-leaflet valve.
60
 The bi-
leaflet is favourable due to its improved clinical performance; however some researchers 
have found the tilting disc valve to have superior hemodynamics if orientated to correspond 
to the eccentric profile of the normal blood flow.
61, 62
  
 
A problem with the bi-leaflet valve was the hinge region which caused recirculation or 
stagnation of blood flow and elevated shear stresses which led to thrombus formation and 
haemolysis.
63
 An interesting bi-leaflet valve which addressed this problem was the 
CardiaMed valve, previously known as the Jyros valve developed in Russia. This valve was 
designed with leaflets that continuously rotated 360° around the central axis of the valve 
housing with every heart beat. This enabled an even distribution of the blood flow across the 
prosthesis, allowing the parts to be washed to prevent thrombus formation. This feature of the 
valve also meant that the valve did not require orientation during the surgical procedure. 
However the objective performance criteria rate for thromboembolism following AVR was 
reportedly higher at 2.98% per year compared to 2% for the St. Jude valve.
64
  
 
As mechanical valves are prone to thrombosis and embolism, patients fitted with a 
mechanical heart valve would constantly require anticoagulation therapy. Additionally, the 
noise produced by the leaflets can reduce patient quality of life. Failure of mechanical valves 
is largely caused by loading, material fatigue and cavitations. The failures led to several 
design modifications such as using PyC which exhibited excellent hemocompatibility and 
remains the material of choice for mechanical heart valves today. 
 
 
Figure 5. Mechanical heart valves: a) ball and cage valve, b) tilting-disc valve and c) bileaflet valve.65 
 
Bioprosthetic valves 
 
A bioprosthetic valve may either be an allograft (cadaver or Ross procedure) or more 
commonly, a xenograft (native or pericardium). The Ross procedure is a heart valve 
replacement procedure popular with surgeons for neonates and children. It involves replacing 
the diseased DRUWLFYDOYHZLWKWKHSDWLHQW¶VRZQ pulmonary valve (pulmonary autograft) and 
replaces the pulmonary valve with an aortic or pulmonary allograft. There are three 
techniques to this method; subcoronary implantation, aortic root replacement or aortic root 
inclusion. The benefits of this procedure are that the pulmonary autograft can grow with the 
patient and will not induce an immunological response. Additionally, less demand is expected 
on the allograft in the pulmonary position. However, two surgical procedures are performed 
and a highly skilled surgeon is required to perform the operation. Common complications 
with this procedure include aortic dilation and insufficiency, due to an increased diameter of 
the sinotubular junction. Dilation was more commonly reported with the root replacement 
12 
 
technique which was attributed to an abnormality of the pulmonary valve in patients with 
congenital aortic valve disease.
66
 
 
The most common xenografts are porcine aortic valves which may be stented or stentless, 
and bovine pericardial valves. A stented valve would incorporate a metal wire folded to 
typically form three prongs which serve as an attachment site for the commissures of the 
valve. The entire wire frame would be covered in Dacron to enable suturing of the tissue to 
the stent. A stentless valve is one where the valve has been excised from the animal with the 
conduit intact. Stentless valves have a hemodynamic advantage over stented valves as they 
provide a greater EOA due to the absence of the stent. The blood is also subjected to less 
shear stress and so the chances of haemolysis due to rupture of the blood cells is reduced. 
However pericardial valves are more easily mass produced as there is no problem with 
supply.
67
 
 
The first popular pericardial valve was the Ionescu±Shiley Pericardial Xenograft valve which 
was developed in 1971 and marketed in 1976. This valve used bovine pericardium sutured 
onto a titanium stent which was covered with a Dacron fabric. Although having superior 
hemodynamics compared to other prosthesis, a series of early structural failures lead to its 
withdrawal in 1987, negatively impacting in pericardium as a material of choice. It was later 
realised that the valves had abrasive tears due to the fabric-tissue interface and due to the 
leaflets calcifying.
67
 These problems were overcome with the Carpentier-Edwards bovine 
pericardial valve in 1980 by stitching the pericardium to the inside of the Dacron fabric rather 
than around it, using flexible stent posts and by removing the sutures that were put in place 
for commissural alignment. 
 
 
 
Figure 6. Bioprosthetic valves: a) Medronic Hancock II Porcine Valve, b) Edwards Pericardial Valve and c) 
Edwards Prima Plus Stentless Porcine Prosthesis. 
 
Biological valve prostheses have excellent hemodynamics compared to mechanical valves 
due to their anatomical structure. However, they are prone to calcification and thus have a 
shorter life span than mechanical valves. Valves and pericardium excised from species need 
to be sterilized and preserved. The most common treatment adopted for the preservation of 
these tissues is their fixation in glutaraldehyde, a five-carbon atom dialdehyde.
68
 The method 
of fixation varies substantially. Some bioprosthetic valves are fixed at 0 mmHg or low 
pressures whereas others are prepared at 80-100 mmHg closing pressures. It was observed 
that when a high pressure fixation is adapted, the pericardium loses its natural collagen crimp 
VWUXFWXUHZKLFKLQFUHDVHVLW¶VVWLIIQHVV.1 This problem could be avoided by fixing the tissue 
under dynamic pressures. Glutaraldehyde fixation has also been found to reduce the GAG 
concentration in valvular leaflets during flexural fatigue, which would compromise the 
structure of the spongiosa layer and may contribute to tissue deterioration and calcification.
69
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Other fixation methods including photo-oxidization and decellularization have been 
considered although the long term effects of these treatments still needs to be determined.
70, 71
  
There are two main causes of bioprosthetic valve failure; mechanical and chemical 
influences. Pericardium and xenografts are prone to calcification particularly in regions 
exposed to high stress which leads to eventual stiffening of the leaflets. However, the highest 
cause of failure come from mechanical stresses alone, indicating the importance of nailing 
valve design.
72
 Other causes of failure included stent rigidity, the level of pressure applied to 
glutaraldehyde fixation and anisotropy between leaflets. 
  
Tissue engineered valves 
 
Tissue engineering is a field in regenerative medicine which aims to restore and maintain the 
function of living tissues through the applied understanding of engineering and biological 
sciences. They have found particular success in skin grafts for burn victims. The perceived 
advantages of tissue engineered heart valves (TEHV) compared to other valve replacement 
options include non-thrombogenicity, infection resistance and cellular viability. It is 
particularly exciting in children and young adults where the possibility exists of a valve 
capable of growing, remodelling and repairing itself as the patient grows.
30
  However their 
design has remained challenging and their success depends on advancements in material 
science and culturing techniques. There have been several TEHV approaches predominately 
to the pulmonary valve including decellularization
73, 74
, biodegradable scaffolds, in-vivo
75
 
and hybrid TEHVs
76
.  
 
Decellularization involves removal of the cellular contents of a native heart valve, keeping 
only the ECM component. This approach has the benefit of decreasing the immunogenicity 
response, enabling xenografts to be suitable in humans. Additionally, the matrix should have 
the desirable mechanical and structural integrity for use as heart valves. However, 
decellularizing the matrix can lead to alterations to the collagen structure, GAG content and 
ECM which may influence the mechanical properties.
77
 The matrix can also be reseeded 
either through coating with a bioactive substance or by seeding with autologous cells, 
although cells have been found to leach out once implanted in vivo. The use of a 
decellularized matrix is also limited since it requires relatively healthy valves which would be 
more suited for allografts. 
 
Biodegradable scaffolds are commonly employed in tissue engineering due to the vast 
availability of synthetic materials with biodegradable properties. The most widely used 
synthetic polymers are polyglycolic (PGA) and polylactic acid (PLA), although natural 
scaffolds such as chitosan have also been considered. The basic idea behind these scaffolds is 
to create a template on which the matrix can synthesize. This requires a careful balance in 
controlling the rate of scaffold degradation with the rate of matrix synthesis so that the cells 
remain seeded on a structurally stable material. However, the final matrix has been found to 
have a lower mechanical strength to the biodegradable scaffold.
78
 Scaffolds are then 
harvested with autologous cells, allogenic cells or stem cells such as mesenchymal stem cells 
(MSC) which should then proliferate to VECs and VICs. Additional signals such as 
cytokines, hormones and growth factors and mechanical stimuli such as bioreactor systems 
are often adopted to improve tissue growth.
19
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Figure 7. Photographs of autologous tissue engineered valve (a) non-woven PGA scaffold coated with P4HB 
from the (a) aortic and (b) ventricular sides. (c) and (d) after 4 weeks of culturing. Adapted from Mol et al.78 
 
Polymeric valves 
 
Polymeric heart valves (Figure 8) combine the durability of mechanical valves with the 
hydrodynamic function of bioprosthetic valves.
80
 They have a huge advantage in that they 
can be manufactured to various shapes and sizes.
81
 In a comparative study of a polyurethane 
valve with a mechanical and bio-prosthetic valve, the former was found to have superior 
hemodynamics compared to the bio-prosthetic valve. Additionally, incidence of 
thrombogenicity was lower than in the mechanical valve.
80
 Polymeric valves have been 
around for over 50 years but failed to gain popularity due to their initial poor characteristics. 
In fact, one of the earliest prosthetic heart valves was a mitral polyurethane valve with a 
Teflon chordae tendineae which was implanted in a 44 year old woman in 1959.
82
 Many of 
the earlier polymeric valves used polymers which were prone to calcification and early 
degradation which prohibited their widespread use. Consequently they were only used in 
VKRUWWHUPµ%ULGJHWR7UDQVSODQWDWLRQ¶GHYLFHVVXFKDVLQWRWDODUWLILFLDOKHDUWVDQGOHIW
ventricular assist devices.  
 
It was the introduction of polyurethane, a two-phased microstructure of hard and soft 
segments which escalated their use as biomaterials. Biomer was the first polyurethane stable 
HQRXJKWREHFRLQHGDVDµELRPDWHULDO¶DQGXVHGWRIRUPWKHSXPSGLDSKUDJPRIWKH-DUYLF
total artificial hearts.
83
 Biomaterial polymers such as silicone, polytetrafluoroethylene 
(Teflon) and polyvinyl alcohol have also been considered as alternative materials to heart 
valves.
79, 84
 However, much of the focus has been on thermoplastic polyurethanes (TPU) 
which have shown potential due to their excellent mechanical properties and bio-stability. 
Advanced material science has enabled development of these polymers with improved 
biostability and durability. Initially these polymers had polyester soft segments which were 
prone to hydrolysis and oxidation. The two-phase microstructure of TPU has enabled 
researchers to improve biostability by modifying the soft segments or through chemical 
substitutions to their structure.
81
  
 
Improving the stability of polyurethanes often involves incorporating silicone into the 
polymer chain. In 1999, Gunatilake et al. developed a polymer with silicone microdiols 
which gave it superior biostability in relation to other TPUs. This polymer is now marketed 
by Aortech International Plc (Rogers, Minnesota) under the name Elast-(RQDQGLVXVHGLQ
the development of heart valves as well as insulation for pacemaker and defibrillator leads.
85-
88
 Another group have developed a polycarbonate urethane with polyhedral oligomeric 
silsesquioxanes (POSS) nanoparticles which they aim to develop thin enough for use in 
TAVR.
89
 Polymeric valves have vast manufacturing possibilities including dip-coating, film 
casting and injection molding. They are promising in the field of percutaneous technologies 
15 
 
due to the ability to control their thickness and create leaflets thin enough for low profile 
TAVR.  
 
Unlike the native valve and pericardium, polymeric materials are strain rate dependant and 
this feature could affect the valve performance and durability if not accounted for in valve 
design. For example, the leaflets could stiffen at increased heart rates which could increase 
opening times or prevent smooth coaptation during diastole. 
 
 
Figure 8. Polymeric heart valves; (a) polymeric valve designed by the University of Strathclyde with Elast-Eon 
leaflets (b) the ADIAM Polycarbonate urethane valve90 and the (c) POSS-PCU valve developed at University 
College London.91  
Complications with AVR and Implications for TAVR 
 
Almost a third of patients with severe AS over the age of 75 years are turned down for AVR 
as the surgical procedure is deemed too risky or due to technical complications such as a 
porcelain aorta, where the aorta is too calcified to allow suturing of a valve.
43
 The mortality 
rate from 2004 to 2008 for AVR alone and with CABG was estimated to be 2.8% and 5.3% 
respectively.
50
 AVR is also not practical in neonates and children who would need frequent 
replacement as they grow, and current bioprosthetic and mechanical valves are too large for 
implantation. Although the Ross Procedure is successful, this technique is technically 
challenging and involves replacing an otherwise healthy pulmonary valve. 
  
In 1992, Andersen et al. demonstrated the feasibility of TAVR by deploying a porcine aortic 
valve sutured and crimped into a balloon expandable stent.
91
 A decade later, Cribier and 
colleagues deployed a transcatheter valve in a patient suffering calcific AS, severe leg 
ischemia and cardiogenic shock but was denied surgery by several surgeons. Immediately 
following the procedure, the transvalvular pressure gradient dropped from 30 mmHg to 6 
mmHg and there was an improvement from 14% to 17% in the left ventricular ejection 
volume.
92
 The major benefit of TAVR is that the valve is deployed over the native valve 
percutaneously without the need for open heart surgery and CPB, enabling patients who are 
refused surgery due to high risk or technical complications to receive valvular replacement. 
There are two leading valves in the market today; the Edwards SAPIEN valve by Edwards 
LifeSciences and the CoreValve Prosthesis by Medtronic Inc.  
 
TAVR was previously only indicated in inoperable high risk patients with severe AS, having 
a EuroScore 20 or an STS PROMS score 10. There is now an increasing drive to perform 
TAVR in operable high and intermediate risk patients and these outcomes are being assessed 
in both the PARTNER II and SURTAVI trials.
93, 94
 However, there are still many 
complications that need to be overcome before TAVR should be considered in lower risk 
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patients, which include paravalvular leakage, stent migration, major vascular complications, 
conduction disturbances and stroke.
95-97
 
 
The distal end of the valvular prosthesis is often positioned below the basal attachment and 
the large diastolic pressures can cause it to migrate into the LVOT. Although rare, late stent 
migration and rotation can occur if the calcific nodules on the native valve are not sufficient 
to anchor the stent, which can lead to paravalvular leakage or obstruction of the LVOT.
98, 99
 
Conversely, although calcific nodules are necessary for stent fixation, their location 
particularly at the aortic wall and valve commissures can be a determinant for paravalvular 
leakage (PVL).
100
 PVL can also occur if there is an annulus-prosthesis mismatch due to 
prosthesis under-sizing.
101
 Balloon post-dilation is often practiced immediately following 
TAVR to minimise PVL although over-dilation can lead to poor leaflet apposition, cerebral 
vascular events or rupture of the aortic annulus.
95, 102, 103
 This can be prevented by ensuring 
the balloon is not larger than the maximum diameter of the aortic valve.
101
 
 
Over-sizing can also increase the risk of conduction abnormalities due to the compression of 
the atrio-ventricular (AV) conduction node or the His bundles. Bleiziffer et al. reported a 2-
fold increase in risk for new onset AV-block if the aortic annulus was at the lower end of the 
recommended size for a specific prosthetic size and a 4-fold increase in risk with the 
CoreValve than the Edwards SAPIEN valve.
104
 There is also an increase in conduction 
disturbances if the stent is positioned too deep into the LVOT. Muñoz-García et al. found a 
&RUH9DOYHLPSODQWDWLRQGHSWKRIPPLQWRWKH/927FRuld be an early indicator of the 
need for a pacemaker and recommend an optimal implantation depth of 6 mm.
105
  
 
Alternatively, positioning the valvular prosthesis supra-annularly can cause coronary ostia 
occlusion, affirming the need for accurate positioning. As TAVR is largely non-invasive, the 
procedure is dependent on imaging techniques such as trans-oesophageal (TEE) and trans-
thoracic (TTE) echocardiography. TEE can however under-estimate the aortic valve area due 
to the ellipsoidal nature of the annulus, leading to patient prosthesis mismatch (PPM). Better 
imaging such as the use of multi-slice (or multi-detector) computed tomography (MSCT) or 
planimetry has been shown to more accurately predict the aortic annulus.
106-108
 Accurate 
imaging is also necessary for patient selection and for determining the most suitable delivery 
route to take. MSCT can provide enhanced three-dimensional reconstructed images to assess 
the degree of arterial tortuosity, calcification and of the aortic root and is commonly adopted 
in pre-procedural assessment.
109, 110
  
 
The current size of transcatheter valves in their collapsed state has been shown to contribute 
to major vascular complications following retrograde delivery through the femoral arteries.
97
  
Calcific debris can also be dislodged from heavily sclerotic arteries during the delivery 
procedure, which can lead to stroke or silent cerebral ischemia.
111
 Consequently, it is 
desirable to decrease the size of the delivery catheter to provide a less invasive and traumatic 
access vessel to the aorta. This can be achieved by enabling delivery to a peripheral artery 
through a minimal or fully percutaneous incision. However this requires the valve to be 
collapsed into a smaller sheath and current percutaneous valves formed from porcine or 
bovine pericardium are too thick to enable this, having thicknesses of 200-400 µm.  
 
 
Conclusions 
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The aortic valve is often considered to be a passive structure, opening and closing as a result 
of pressure changes. It in fact responds in an intricate and dynamic manner to flow changes 
during the cardiac cycle by structurally adapting to the complex hemodynamic environment. 
Their ability to dynamically adapt to changes creates an obstacle in prosthetic valve design to 
overcome problems including durability, thrombogenicity, haemolysis and calcification. 
Deviating from the native tri-leaflet design of the valve leads to changes in mechanical and 
hemodynamic responses of the valve, which can increase shear stress, commissural and belly 
stresses and strains on the leaflet free edge. Therefore it is imperative that considerations are 
made to minimise leaflet stresses and create outflow patterns that mimic the native valve. 
 
Polymeric valves combine the hemocompatibility of bioprosthetic valves with the durability 
of mechanical valves, providing an optimal material of choice, as well as providing enough 
stability to not necessitate anti-coagulation treatment. Polymers also have vast manufacturing 
options to produce various valve designs. Thus they can be optimally designed to crimp into a 
small vessel with minimal structural damage to the leaflets. An ultra-thin synthetic leaflet 
material is hoped to overcome the complications related to the current femoral arterial access 
by enabling a lower profile delivery though a peripheral artery. Prosthetic valve development 
will never identically replicate the characteristics of the native valve. However the goal is to 
work towards a fully functional and durable prosthesis, capable of regulating the one way 
flow of blood through the heart.  
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